Description
REZDIFFRA (resmetirom) tablets
FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease
U.S. Food and Drug Administration approved Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), to be used along with diet and exercise.
NASH is a result of the progression of nonalcoholic fatty liver disease where liver inflammation, over time, can lead to liver scarring and liver dysfunction. NASH is often associated with other health problems such as high blood pressure and type 2 diabetes.
Get Access to REZDIFFRA (resmetirom) tablets In India
On request it available to patient and doctors. Medvitaz Pharma is equipped to facilitate the distribution of REZDIFFRA (resmetirom) tablets (prescription medications) worldwide and throughout India upon completion of necessary legal procedures, if applicable.
To inquire about the price of either the branded medication “REZDIFFRA (resmetirom) tablets” or the generic version “resmetirom tablets” for personal use under patient-specific treatment in various cities including Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Surat, Jaipur, Coimbatore, Noida, Gurgaon, Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim, and others in India, please fill out the request form. Upon receiving your request and assessing the delivery process, we will provide you with an estimated price for the medication within 24 hours.
For any inquiries or assistance, please reach out to our Patient Support Team. We are available to assist you from Monday to Friday, between 9:00 and 19:00 IST. You can contact us via email at [email protected], toll-free at +91 8750295029, or through WhatsApp at +91-8750295029.
References
1. U.S. Food and Drug Administration.FDA approves first treatment for patients with liver scarring due to fatty liver disease. FDA 2024 Mar 14; [e-pub]. (https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease)
2. Harrison SA et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med 2024 Feb 8; 390:497. (https://doi.org/10.1056/NEJMoa2309000)
3. Leo L and Sunny ME. US FDA approves first drug for fatty liver disease NASH. Reuters 2024 Mar 14; [e-pub]. (https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-first-drug-fatty-liver-disease-nash-2024-03-14)
4. Institute for Clinical and Economic Review.ICER publishes final evidence report on treatments for non-alcoholic steatohepatitis. ICER 2023 May 25; [e-pub]. (https://icer.org/news-insights/press-releases/icer-publishes-final-evidence-report-on-treatments-for-non-alcoholic-steatohepatitis/)
5. Cusi K. Selective agonists of thyroid hormone receptor beta for the treatment of NASH. N Engl J Med 2024 Feb 8; 390:559. (https://doi.org/10.1056/NEJMe2314365)
